PTC THERAPEUTICS INC. overview

PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category - New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 - PR Newswire SOUTH PLAINFIELD, N.J., Jan. 14, 2021 SOUTH PLAINFIELD, N.J. , Jan. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the seventh annual STRIVE Awards program for Duchenne...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH PLAINFIELD, N.J., Jan. 13, 2021 SOUTH PLAINFIELD, N.J. , Jan. 13, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggregate of 13,465 shares of its common stock and 4,665 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 10 new...

PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference - ~$333 million preliminary unaudited 2020 total net product revenue representing 14% year-over-year growth - - Huntington splicing program healthy volunteer data expected 1H 2021 - - Multiple late-stage clinical programs advancing with six registration-directed trials - - 2021 Duchenne franchise revenue guidance of $355-$375 million - PR Newswire SOUTH PLAINFIELD, N.J., Jan....

PTC Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH PLAINFIELD, N.J., Jan. 4, 2021 SOUTH PLAINFIELD, N.J. , Jan. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11 th at 7:30 a.m. EST . The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH PLAINFIELD, N.J., Dec. 18, 2020 SOUTH PLAINFIELD, N.J. , Dec. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an aggregate of 12,500 shares of its common stock and 4,360 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 10...

PTC Therapeutics to Host Translarna™ Deep Dive Webinar PR Newswire SOUTH PLAINFIELD, N.J., Dec. 9, 2020 SOUTH PLAINFIELD, N.J. , Dec. 9, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET . The Translarna Deep Dive will provide an overview of results from the clinical and real-world data generated to date for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD)...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH PLAINFIELD, N.J., Dec. 4, 2020 SOUTH PLAINFIELD, N.J. , Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggregate of 41,955 shares of its common stock and 20,735 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 47 new...

PTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy PR Newswire SOUTH PLAINFIELD, N.J., Dec. 4, 2020 SOUTH PLAINFIELD, N.J. , Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD). It is estimated that 13% of DMD patients have a nonsense mutation. In countries where it is...

PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia - Third trial initiated in 2020 from compounds identified from PTC's Bio-e platform - PR Newswire SOUTH PLAINFIELD, N.J., Nov. 30, 2020 SOUTH PLAINFIELD, N.J. , Nov. 30, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the registration-directed Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults with...

PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference PR Newswire SOUTH PLAINFIELD, N.J., Nov. 19, 2020 SOUTH PLAINFIELD, N.J. , Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1 st at 11:45 a.m. ET . The presentation will be webcast live on the Events and Presentations page under the investor relations section of...

PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications PR Newswire SOUTH PLAINFIELD, N.J., Nov. 18, 2020 SOUTH PLAINFIELD, N.J. , Nov. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted PTC596 both Orphan Drug Designation and Fast Track designation for the potential treatment of leiomyosarcoma (LMS), a rare type of cancer that...

PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program - Initial clinical trial results expected in 1H 2021 - PR Newswire SOUTH PLAINFIELD, N.J., Nov. 17, 2020 SOUTH PLAINFIELD, N.J. , Nov. 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC's splicing platform and is being developed for the...

PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases - AADC deficiency associated with high and accumulating disease burden, demonstrating the need for access to an effective therapy - - Patient and caregiver quality of life study reveals real-life impact of nonsense mutation Duchenne muscular dystrophy and reinforces value of treatment - PR Newswire SOUTH PLAINFIELD, N.J., Nov. 16, 2020 SOUTH PLAINFIELD, N.J. , Nov. 16, 2020 /PRNewswire/ -- PTC...

PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update - Evrysdi™ makes rapid progress with multiple international approvals and strong U.S. launch - - Total net revenue of $118.4 million, 66% YoY increase; Total net product revenue of $82.7 million, 16% YoY increase - - Initiated registration-directed trial with vatiquinone (PTC743) for mitochondrial epilepsy - PR Newswire SOUTH PLAINFIELD, N.J., Oct. 29, 2020 SOUTH PLAINFIELD, N.J. , Oct. 29, 2020...

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH PLAINFIELD, N.J., Oct. 28, 2020 SOUTH PLAINFIELD, N.J. , Oct. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of 18,610 shares of its common stock and 6,860 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18...